Nigeria’s drug regulator has spent seven years phasing out imports of medicines that local plants can make. Under NAFDAC’s 5+5 policy and its Ceiling List, importers of listed products must build a Nigerian plant or move production to a Nigerian contract manufacturer. Local production has risen to about half the market, and contract manufacturing has grown from 10 companies to 87, but high power costs and imported APIs still squeeze the plants doing the work.
NAFDAC 5+5 policy: latest updates
- Nov 22, 2026: NAFDAC reported that more than 70% of finished products covered by the 5+5 policy and Ceiling List are now made locally, and that it is pursuing WHO Maturity Level 4.
- Nov 11, 2026: Health Minister Muhammad Ali Pate said the 2024 executive order on local production had supported N24 billion in tax waivers for drug manufacturers in 2025 and 2026, alongside 12 technology transfer agreements.
- Oct 28, 2026: NAFDAC updated its Ceiling List and will no longer accept new registrations for imported products on it. Renewals of existing registrations must go through the 5+5 pathway.
- Oct 2, 2026: The federal government signaled plans to extend the executive order supporting local manufacturing by two more years.
NAFDAC 5+5 policy at a glance
| Region | Nigeria |
| Instrument | NAFDAC 5+5 regulatory directive (2019) and Pharmaceutical Ceiling List; Presidential Executive Order on local production of healthcare products (2024) |
| Legal status | In force. Ceiling List updated October 28, 2026 |
| Key dates | Apr 2019: 5+5 directive. Jul 2024: executive order. Oct 28, 2026: Ceiling List update. Mar 2027: executive order window due to close |
| Most exposed | Importers and foreign marketing authorization holders of listed generics; Nigerian contract manufacturers; API and excipient suppliers |
| Official source | NAFDAC: The Pharmaceutical Industry and the Impact of the 5+5 Policy |
| PharmaSource Score | 135 Impact 5, Reach 3, Likelihood 9 Download the PharmaSource Regulatory Radar |
What the NAFDAC 5+5 policy is
NAFDAC created the 5+5 policy in 2019 after a survey found that the top five imported drugs were also the top five made in Nigeria. The directive phases out imports of selected products and asks importers to set up a local plant or contract manufacture with a suitable Nigerian partner. Its stated goal is to move Nigeria from 70% imported medicines to 70% made locally.
- Five plus five years: An imported product’s registration is valid for five years. Importers must present a local manufacturing blueprint, and a final five-year renewal depends on a verifiable plan to make the product in Nigeria.
- Ceiling List: Products on the list are restricted from import. The list grew from nine products in 2020 to 36, and since October 2026 NAFDAC accepts no new import registrations for listed products.
- Contract manufacturing route: Foreign companies can keep their products in the market by transferring them to a qualified Nigerian manufacturer instead of building a plant.
- Executive order incentives: A 2024 presidential order grants zero tariffs and excise duties on pharmaceutical machinery and equipment, waivers on APIs and excipients, and framework contracts with volume guarantees, for two years from its effective date.
- Pooled demand: The government is setting up Medipool, a group purchasing organization to consolidate public demand for medicines.
Where the NAFDAC 5+5 policy stands
NAFDAC says the policy and the Ceiling List have cut imports of affected medicines by 70% and moved the import-to-local ratio from 70:30 in 2019 to 50:50 in 2025. The number of drug manufacturers rose from 174 to 190, and 176 companies had their facility layouts reviewed and approved by June 2026. The policy has produced 28 new or retrofitted companies and 16 new facilities, according to NAFDAC Director-General Mojisola Adeyeye.
- Apr 2019: NAFDAC issues the 5+5 directive.
- 2020: First Ceiling List covers nine products.
- 2023: GSK and Sanofi announce their exits from Nigeria.
- Jul 2024: President Tinubu signs the executive order on local healthcare manufacturing.
- Sep 2026: NAFDAC reports 36 products on the Ceiling List and 87 companies in contract manufacturing.
- Oct 28, 2026: Ceiling List updated; new import registrations for listed products end.
- Mar 2027: Current executive order window expected to close, unless extended.
What the Nigeria NAFDAC 5+5 policy means for manufacturing and outsourcing
The policy has turned Nigeria into a contract manufacturing market. Companies involved in contract manufacturing rose from 10 in 2019 to 87 in 2026, as importers chose partners over new plants.
- Sponsors and foreign generics makers: For any product on the Ceiling List, the import route is closing. Keeping the product in Nigeria means a tech transfer to a local manufacturer or a local plant, with a blueprint filed well before the registration’s renewal.
- Nigerian CDMOs: Demand is strong, but plants carry costs that Asian competitors do not. Pharmaceutical companies spend more than 40% of revenue on power, according to the Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria (PMG-MAN).
- API and excipient suppliers: Local production still depends on imported inputs, which makes Nigerian plants a growing customer for API makers abroad. The executive order’s waivers on APIs and excipients lower that cost while they last.
- Equipment suppliers: Zero tariffs on machinery favor plant builds and upgrades before the incentive window closes.
- Regional exporters: NAFDAC holds WHO Maturity Level 3 status and is pursuing Level 4, which supports Nigerian-made products in regional markets.
For outsourcing leaders, the practical step is to check every Nigerian registration against the updated Ceiling List, then qualify a Nigerian contract manufacturer for listed products and confirm its power, API supply and GMP status before renewal deadlines fall.
Why supporters back the NAFDAC 5+5 policy
“Our task is to help those prospective investments become operating businesses.”
Muhammad Ali Pate, Coordinating Minister of Health and Social Welfare, Premium Times
- Medicine security: The 2023 exits of GSK and Sanofi left gaps in supply, and supporters argue that local production protects patients from such shocks.
- Investment: Pate cites 12 technology transfer agreements and a prospective investment pipeline above $5 billion, and the Presidential Initiative for Unlocking the Healthcare Value Chain has secured about $2 billion in financing commitments.
- Measurable results: Locally made medicines rose from 30% of the market in 2023 to 50% in 2026, according to Minister of State Iziaq Salako.
- Regulatory credibility: Sustained WHO Maturity Level 3 status gives regulators and procurement agencies abroad more confidence in products from NAFDAC-licensed plants.
Criticisms of the NAFDAC 5+5 policy
“High energy costs and delayed clearance of pharma inputs remain a major threat.”
Frank Muonemeh, Executive Secretary, PMG-MAN, NewsPeddlers
- Imported inputs: Local plants still import their APIs, so naira weakness and port delays pass straight into costs. NAFDAC’s own director-general has noted that local manufacturers import everything.
- Prices and access: After multinational exits, prices for some drugs rose by as much as 1,100%, according to SBM Intelligence, and high prices push patients toward falsified medicines.
- Thin capacity: Capacity utilization in the sector has been estimated at about 40%, so import restrictions can run ahead of plants’ ability to supply reliably.
- Short incentive window: PMG-MAN wants the executive order support extended from two to five years, along with dedicated industrial power tariffs and faster port clearance.
What’s next for the NAFDAC 5+5 policy
- Executive order extension: The current window is expected to close in March 2027. Watch whether the government extends it by two years, as signaled, or by the five years industry wants.
- More Ceiling List products: Each update moves more products from import to local supply.
- Local API production: Emzor’s $23 million API plant in Sagamu, billed as the first of its kind in sub-Saharan Africa, is the test of whether Nigeria can move beyond formulation.
- WHO Maturity Level 4: A higher rating would strengthen the case for Nigerian-made medicines across the region.
- Our score: Impact 5, because import limits force local sourcing for listed products. Reach 3, because the effect falls on sponsors and generics makers selling in Nigeria. Likelihood 9, because the policy is running and the list keeps growing. That gives a PharmaSource Score of 135.
Related articles
- Egypt Pharma Localization: Import Bans, API Targets and a Fast Track for Export Plants
- Gavi African Vaccine Manufacturing Accelerator (AVMA): How Africa Pays for Vaccine Tech Transfer
- Saudi Arabia Pharma Localization: How NUPCO Tenders Push Drugmakers to Build in the Kingdom
- Brazil’s Productive Development Partnerships Explained: Guaranteed Public Demand for Technology Transfer
- IAVI Partners with Minapharm and ProBioGen to Expand Vaccine and mAb Manufacturing in Africa